Last updated: February 20, 2026
What is NDC 73352-0510?
NDC 73352-0510 refers to a drug product marketed under a specific National Drug Code. This code is assigned by the FDA to identify drug products precisely. Based on available databases, NDC 73352-0510 is associated with Xellia's Vancomycin HCl for Injection, 500 mg/vial.
Market Overview
Product Specification
- Active Ingredient: Vancomycin HCl
- Formulation: Intravenous (IV) injection
- Strength: 500 mg per vial
- Manufacturer: Xellia Pharmaceuticals
Therapeutic Area
Vancomycin is a glycopeptide antibiotic primarily used to treat severe bacterial infections, including MRSA (Methicillin-resistant Staphylococcus aureus) infections, endocarditis, and septicemia. It remains a critical component in hospital settings.
Market Size
- Global Market (2022): Estimated at approximately USD 1.2 billion, with growth driven by rising antibiotic resistance.
- U.S. Market (2022): Accounts for roughly USD 600 million; used primarily in hospital environments.
- Market Drivers:
- Increasing antibiotic resistance necessitating potent antibiotics
- Rising prevalence of healthcare-associated infections
- Expansion in hospital admissions for severe infections
Competitive Landscape
The market includes both innovator and generic products. Major competitors include:
| Company |
Product Name |
Formulation |
Market Share (2022) |
Pricing (per 500 mg vial) |
| Xellia |
Vancomycin HCl, 500 mg vial |
Injectable |
45% |
USD 20-25 |
| Fresenius Kabi |
Vancomycin, 500 mg vial |
Injectable |
25% |
USD 22-27 |
| Sandoz |
Vancomycin, 500 mg vial |
Injectable |
15% |
USD 21-26 |
| Others |
Various generics |
Injectable |
15% |
USD 18-24 |
Pricing Trends
- Price per vial has increased modestly over the past 5 years, driven by manufacturing costs and supply chain constraints.
- There is limited price variation among generic manufacturers, indicating competitive parity.
Price Projections
Short-Term (Next 1-2 Years)
- Wholesale acquisition cost (WAC) expected to remain within USD 20-25 per 500 mg vial.
- Slight upward pressure due to inflation, supply chain costs, and increased demand in hospital settings.
- No significant price reductions anticipated because of limited competition among high-demand antibiotics.
Long-Term (Next 3-5 Years)
- Prices are projected to stabilize or increase marginally (USD 22-28 range).
- Introduction of biosimilars or new formulations could influence prices, but none are currently slated for release.
- Market growth rate of 2-3% annually, maintaining high demand for established products.
Factors Affecting Price Changes
- Antibiotic stewardship initiatives that may limit overuse.
- Supply chain disruptions, such as raw material shortages.
- Regulatory policies affecting drug pricing and reimbursement.
Regulatory and Policy Impact
- The FDA's ongoing efforts to combat antimicrobial resistance emphasize careful monitoring of vancomycin use.
- Potential for price regulation, especially if used extensively in government-funded healthcare programs.
Summary of Market Outlook
| Aspect |
Outlook |
| Market Growth |
2-3% annually in the next 5 years |
| Price Stability |
Remain within USD 20-28 range |
| Competitive Dynamics |
Moderate, with no major price shifts expected |
| Supply Chain Risks |
Potential to influence short-term prices |
Key Takeaways
- NDC 73352-0510 is associated with vancomycin HCl injection, 500 mg/vial.
- Market size is approximately USD 600 million in the U.S., expanding worldwide.
- Prices are relatively stable with slight upward pressure, expected to stay within USD 20-28 per vial.
- Market is mature, with limited new entrants and moderate competition among generics.
- Regulatory trends and supply chain stability will influence future pricing.
FAQs
Q1: How does the price of NDC 73352-0510 compare to other antibiotics?
A1: It is generally priced higher than many generic antibiotics due to its critical role in resistant infections and manufacturing costs, with prices around USD 20-25 per 500 mg vial.
Q2: Are there any upcoming generic entrants that could lower prices?
A2: Currently, the market has several generic manufacturers with stable market shares. No new entrants are expected soon.
Q3: What factors could drive significant price changes?
A3: Supply chain disruptions, regulatory actions, or new formulations could influence prices, but none are imminent.
Q4: Is there potential for biosimilar or alternative formulations?
A4: As of 2023, no biosimilars or alternative formulations are approved specifically for vancomycin.
Q5: How does antimicrobial stewardship impact the market?
A5: Stewardship programs limit overuse, potentially reducing demand growth and influencing pricing strategies.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- US Food and Drug Administration (FDA). (2022). NDC Directory.
- MarketWatch. (2022). Antibiotics Market Analysis.
- Statista. (2022). Global Antibiotics Market Revenue.
- Sandoz. (2022). Product Information for Vancomycin.
